Psoriasis is a chronic, inflammatory autoimmune skin disease that can affect children, adolescents, and adults. Given the limited number of therapies approved for pediatric psoriasis, treatment of this population is very challenging. Topical corticosteroids are associated with more-frequent and more-severe adverse events in children, and only two biologics, Amgen’s Enbrel and Janssen’s Stelara, are approved for pediatric and adolescent psoriasis patients, respectively. Topical corticosteroids continue to dominate in terms of patient share among targeted therapies; biologics, although used in later lines of therapy, are experiencing an increase in patient share, reflecting physicians’ growing acceptance of biological therapy use. The use of conventional systemics appears to be declining, underscoring a growing need for treatments with more-acceptable safety profiles.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.